Loading...
•
Sep 25, 2021
Hologic Q4 2021 Earnings Report
Hologic's Q4 2021 earnings exceeded expectations despite a decrease in COVID-19 assay sales.
Key Takeaways
Hologic announced strong Q4 2021 results, with revenue exceeding expectations. The company's diversified business, particularly in women's health, drove growth despite a decline in COVID-19 assay sales compared to the prior year period. Hologic is guiding for continued growth in fiscal year 2022, driven by core women’s health businesses and contributions from COVID-19 testing.
Revenue reached $1.317 billion, a decrease of 2.3% year-over-year, driven by lower COVID-19 assay sales.
Global revenue from Breast Health and GYN Surgical divisions grew 15.6% and 21.8%, respectively.
Diagnostics revenue decreased by 10.9%, but excluding COVID-19 assays, grew by 5.1%.
The company acquired Bolder Surgical for approximately $160 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Hologic expects strong financial results in fiscal 2022, with solid growth in core women’s health businesses and a meaningful contribution from COVID-19 testing.
Positive Outlook
- Expects strong financial results in fiscal 2022.
- Solid growth in core women’s health businesses.
- Meaningful contribution from COVID-19 testing.
- Acessa will be included in organic revenue for the full year.
- Biotheranostics and Diagenode will become part of organic revenue in the fiscal third quarter.
Challenges Ahead
- Revenue $3,750 - $4,000 (33.4%) to (29.0%)
- GAAP EPS $2.50 - $2.80 (65.3%) to (61.2%)
- Non-GAAP EPS $3.55 - $3.85 (57.8%) to (54.2%)
- Q1 2022 Revenue $1,100 - $1,150 (31.7%) to (28.6%)
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...